Wuhan Zhongyuan Huadian Science & Technology Co (300018) Fair Value & Analysis
Industrials · CN · Market cap 6.1B CNY
Analysis
Wuhan Zhongyuan Huadian Science & Technology Co (300018) currently trades at ¥13.71, while our model-based Fair Value estimate is ¥3.31 — implying the stock looks roughly 75.9% overvalued today. We read business quality at 92/100 (high quality), in the Industrials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Wuhan Zhongyuan Huadian Science & Technology Co.,Ltd. engages in the smart grid, healthcare, and industrial investment businesses in China. The company offers power system dynamic recording systems, power system time synchronization and measurement systems, smart grid instruments, substation integrated automation systems, distribution network dispatching and integrated automation systems, energy internet system integration, and intelligent equipment; and fault recording waveform, time synchronization, power grid monitoring, information systems, intelligent inspection, power system relay protection testing and distribution network testing equipment, power data recording and analysis equipment, power time measurement and time scale output equipment, and power system integrated testing equipment. It also provides maintenance, commissioning, and operation services for substations and distribution networks, as well as planning, design, consulting, and operation, and maintenance services …
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.